1 型糖尿病

American Diabetes Association. Standards of medical care in diabetes - 2018. Diabetes Care. 2018;41(suppl 1):S1-159.

• 全文

International Diabetes Federation. Diabetes atlas 8th edition. 2017 [internet publication].

• 全文

Ly TT, Nicholas JA, Retterath A, et al. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013 Sep 25;310(12):1240-7.

• 全文
• 摘要

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.

• 全文
• 摘要

1.  American Diabetes Association. Standards of medical care in diabetes - 2018. Diabetes Care. 2018;41(suppl 1):S1-159.

• 全文

2.  Fourlanos S, Perry C, Stein MS, et al. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care. 2006;29:970-975.

• 摘要

3.  International Diabetes Federation. Diabetes atlas 8th edition. 2017 [internet publication].

• 全文

4.  Centers for Disease Control and Prevention. National diabetes statistics report, 2017. July 2017 [internet publication].

• 全文

5.  Niskanen L, Tuomi T, Karjalainen J, et al. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care. 1995 Dec;18(12):1557-65.

• 摘要

6.  Onkamo P, Vaananen S, Karvonen M, et al. Worldwide increase in incidence of type I diabetes - the analysis of the data on published incidence trends. Diabetologia. 1999 Dec;42(12):1395-403.

• 全文
• 摘要

7.  EURODIAB ACE Study Group. Variation and trends in incidence of childhood diabetes in Europe. Lancet. 2000 Mar 11;355(9207):873-6.

• 摘要

8.  Mayer-Davis EJ, Lawrence JM, Dabelea D, et al; SEARCH for Diabetes in Youth Study. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017 Apr 13;376(15):1419-29.

• 全文
• 摘要

9.  Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell. 1996;85:291-297.

• 摘要

10.  Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ. 2004 Mar 27;328(7442):750-4.

• 全文
• 摘要

11.  Hober D, Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat Rev Endocrinol. 2010 May;6(5):279-89.

• 摘要

12.  Ginsberg-Fellner F, Witt ME, Fedun B, et al. Diabetes mellitus and autoimmunity in patients with the congenital rubella syndrome. Rev Infect Dis. 1985 Mar-Apr;7(suppl 1):S170-6.

• 摘要

13.  Hypponen E, Laara E, Reunanen A, et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001 Nov 3;358(9292):1500-3.

• 摘要

14.  Virtanen SM, Knip M. Nutritional risk predictors of beta cell autoimmunity and type 1 diabetes at a young age. Am J Clin Nutr. 2003 Dec;78(6):1053-67.

• 全文
• 摘要

15.  Marjamaki L, Niinisto S, Kenward MG, et al. Maternal intake of vitamin D during pregnancy and risk of advanced beta cell autoimmunity and type 1 diabetes in offspring. Diabetologia. 2010 Aug;53(8):1599-607.

• 全文
• 摘要

16.  Knip M, Virtanen SM, Seppa K, et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med. 2010 Nov 11;363(20):1900-8.

• 全文
• 摘要

17.  Knip M, Virtanen SM, Akerblom HK. Infant feeding and the risk of type 1 diabetes. Am J Clin Nutr. 2010 May;91(5):1506S-13S.

• 全文
• 摘要

18.  Fronczak CM, Barón AE, Chase HP, et al. In utero dietary exposures and risk of islet autoimmunity in children. Diabetes Care. 2003 Dec;26(12):3237-42.

• 全文
• 摘要

19.  Akerblom HK, Virtanen S, Ilonen J, et al, the National TRIGR Study Groups. Dietary manipulation of beta cell autoimmunity in infants at increased risk for type I diabetes: a pilot study. Diabetologia. 2005 May;48(5):829-37.

• 全文
• 摘要

20.  Kakleas K, Karayianni C, Critselis E, et al. The prevalence and risk factors for coeliac disease among children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract. 2010;90:202-208.

• 摘要

21.  Ludvigsson JF, Ludvigsson J, Ekbom A, et al. Celiac disease and risk of subsequent type 1 diabetes: a general population cohort study of children and adolescents. Diabetes Care. 2006;29:2483-2488.

• 全文
• 摘要

22.  Ziegler AG, Hummel M, Schenker M, et al. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB study. Diabetes. 1999 Mar;48(3):460-8.

• 摘要

23.  Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA. 2007 Oct 23;104(43):17040-5.

• 全文
• 摘要

24.  Garg R, Chaudhuri A, Munschauer F, et al. Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke. 2006 Jan;37(1):267-73.

• 全文
• 摘要

25.  Hyttinen V, Kaprio J, Kinnunen L, et al. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes. 2003 Apr;52(4):1052-5.

• 全文
• 摘要

26.  Gillespie K. Type 1 diabetes: pathogenesis and prevention. CMAJ. 2006 Jul 18;175(2):165-70.

• 全文
• 摘要

27.  Gillespie KM, Bain SC, Barnett AH, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet. 2004 Nov 6-12;364(9446):1699-700.

• 摘要

28.  Dosch HM, Becker DJ. Infant feeding and autoimmune diabetes. Adv Exp Med Biol. 2002;503:133-40.

• 摘要

29.  Borch-Johnsen K, Joner G, Mandrup-Poulsen T, et al. Relation between breast-feeding and incidence rates of insulin-dependent diabetes mellitus. Lancet. 1984 Nov 10;2(8411):1083-6.

• 摘要

30.  Gale EA. The discovery of type 1 diabetes. Diabetes. 2001;50:217-226.

• 摘要

31.  Karvonen M, Pitkaniemi J, Tuomilehto J. The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care. 1999;22:1066-1070.

• 摘要

32.  Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab. 2010;95:25-33.

• 全文
• 摘要

33.  Chiang JL, Kirkman MS, Laffel LM, et al; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014 Jul;37(7):2034-54.

• 全文
• 摘要

34.  Diabetes UK. Self-monitoring of blood glucose levels for adults with type 1 diabetes. March 2017 [internet publication].

• 全文

35.  Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011 Jul 7;343:d3805.

• 全文
• 摘要

36.  Chatterjee S, Davies MJ, Heller S, et al. Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes Endocrinol. 2018 Feb;6(2):130-42.

• 摘要

37.  Christie D, Thompson R, Sawtell M, et al. Structured, intensive education maximising engagement, motivation and long-term change for children and young people with diabetes: a cluster randomised controlled trial with integral process and economic evaluation - the CASCADE study. Health Technol Assess. 2014 Mar;18(20):1-202.

• 全文
• 摘要

38.  Miculis CP, Mascarenhas LP, Boguszewski MC, et al. Physical activity in children with type 1 diabetes [in Portuguese]. J Pediatr (Rio J). 2010 Jul-Aug;86(4):271-8.

• 全文
• 摘要

39.  Riddell MC, Gallen IW, Smart CE, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol. 2017 May;5(5):377-90.

• 摘要

40.  Misso ML, Egberts KJ, Page M, et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010;(1):CD005103.

• 全文
• 摘要

41.  Beck RW, Buckingham B, Miller K, et al; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2009 Nov;32(11):1947-53.

• 全文
• 摘要

42.  Ly TT, Nicholas JA, Retterath A, et al. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013 Sep 25;310(12):1240-7.

• 全文
• 摘要

43.  Monami M, Lamanna C, Marchionni N, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol. 2010 Dec;47(suppl 1):77-81.

• 摘要

44.  Li XL. Multiple daily injections versus insulin pump therapy in patients with type 1 diabetes mellitus: a meta analysis. J Clin Rehabil Tissue Eng Res. 2010;14:8722-5.

45.  Cummins E, Royle P, Snaith A, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess. 2010 Feb;14(11):iii-iv;xi-xvi;1-181.

• 全文
• 摘要

46.  Kordonouri O, Hartmann R, Danne T. Treatment of type 1 diabetes in children and adolescents using modern insulin pumps. Diabetes Res Clin Pract. 2011 Aug;93(suppl 1):S118-24.

• 摘要

47.  Singh, SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009 Feb 17;180(4):385-97.

• 全文
• 摘要

48.  Fatourechi M, Kudva Y, Murad MH, et al. Clinical review: hypoglycemia with intensive insulin therapy: a systematic review and meta-analysis of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab. 2009 Mar;94(3):729-40.

• 全文
• 摘要

49.  Karges B, Schwandt A, Heidtmann B, et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA. 2017 Oct 10;318(14):1358-66.

• 摘要

50.  REPOSE Study Group. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ. 2017 Mar 30;356:j1285.

• 全文
• 摘要

51.  Burdick P, Cooper S, Horner B, et al. Use of a subcutaneous injection port to improve glycemia control in children with type 1 diabetes. Pediatr Diabetes. 2009 Apr;10(2):116-9.

• 摘要

52.  Kaiserman K, Rodriguez H, Stephenson A, et al. Continuous subcutaneous infusion of insulin lispro in children and adolescents with type 1 diabetes mellitus. Endocr Pract. 2012 May-Jun;18(3):418-24.

• 摘要

53.  Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012 Sep 4;157(5):336-47.

• 全文
• 摘要

54.  Langendam M, Luijf YM, Hooft L, et al. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2012;(1):CD008101.

• 全文
• 摘要

55.  Beck RW, Riddlesworth T, Ruedy K, et al; DIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017 Jan 24;317(4):371-8.

• 全文
• 摘要

56.  Benkhadra K, Alahdab F, Tamhane S, et al. Real-time continuous glucose monitoring in type 1 diabetes: a systematic review and individual patient data meta-analysis. Clin Endocrinol (Oxf). 2017 Mar;86(3):354-60.

• 摘要

57.  Petrie JR, Peters AL, Bergenstal RM, et al. Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care. 2017 Dec;40(12):1614-21.

• 全文
• 摘要

58.  Hirsch IB. Clinical review: realistic expectations and practical use of continuous glucose monitoring for the endocrinologist. J Clin Endocrinol Metab. 2009 Jul;94(7):2232-8.

• 全文
• 摘要

59.  Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010 Jul 22;363(4):311-20.

• 全文
• 摘要

60.  Raju B, Arbelaez AM, Breckenridge SM, et al. Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments. J Clin Endocrinol Metab. 2006 Jun;91(6):2087-92.

• 全文
• 摘要

61.  Barnard KD, Skinner TC, Peveler R. The prevalence of co-morbid depression in adults with type 1 diabetes: systematic literature review. Diabet Med. 2006 Apr;23(4):445-8.

• 摘要

62.  Anderson RJ, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001 Jun;24(6):1069-78.

• 全文
• 摘要

63.  American Diabetes Association. Psychosocial factors affecting adherence, quality of life, and well-being: helping patients cope. In: Kaufman FR, ed. Medical management of type 1 diabetes. 5th ed. Alexandria, VA: American Diabetes Association; 2008:173-93.

64.  Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care. 2008 May;31(5):1060-79.

• 全文
• 摘要

65.  Becerra JE, Khoury MJ, Cordero JF, et al. Diabetes mellitus during pregnancy and the risk for specific birth defects: a population-based case-control study. Pediatrics. 1990 Jan;85(1):1-9.

• 摘要

66.  Mathiesen ER, Hod M, Ivanisevic M, et al; Detemir in Pregnancy Study Group. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care. 2012 Oct;35(10):2012-7.

• 全文
• 摘要

67.  Feig DS, Donovan LE, Corcoy R, et al; CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017 Nov 25;390(10110):2347-59. [Erratum in: Lancet. 2017 Nov 25;390(10110):2346.]

• 全文
• 摘要

68.  Farrar D, Tuffnell DJ, West J, et al. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev. 2016;(6):CD005542.

• 全文
• 摘要

69.  Pullman J, Darsow T, Frias JP. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vasc Health Risk Manag. 2006;2(3):203-12.

• 全文
• 摘要

70.  Dunn FL, Nathan DM, Scavini M, et al. Long-term therapy of IDDM with an implantable insulin pump. The Implantable Insulin Pump Trial Study Group. Diabetes Care. 1997 Jan;20(1):59-63.

• 摘要

71.  Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006 Sep 28;355(13):1318-30.

• 全文
• 摘要

72.  Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005 Jul;54(7):2060-9.

• 全文
• 摘要

73.  US Food and Drug Administration. FDA approves Afrezza to treat diabetes. June 2014 [internet publication].

• 全文

74.  Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008 Oct 30;359(18):1909-20.

• 全文
• 摘要

75.  Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011 Aug 6;378(9790):487-97.

• 全文
• 摘要

76.  Pescovitz MD, Greenbaum CJ, Bundy B, et al; Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care. 2014 Feb;37(2):453-9.

• 全文
• 摘要

77.  Rewers M, Gottlieb P. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabetes Care. 2009 Oct;32(10):1769-82.

• 全文
• 摘要

78.  Akirav E, Kushner JA, Herold KC. Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes. 2008 Nov;57(11):2883-8.

• 全文
• 摘要

79.  Vella S, Buetow L, Royle P, et al. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010 May;53(5):809-20.

• 全文
• 摘要

80.  DeGeeter M, Williamson B. Alternative agents in type 1 diabetes in addition to insulin therapy: metformin, alpha-glucosidase inhibitors, pioglitazone, GLP-1 agonists, DPP-IV inhibitors, and SGLT-2 inhibitors. J Pharm Pract. 2016 Apr;29(2):144-59.

• 摘要

81.  Petrie JR, Chaturvedi N, Ford I, et al; REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Aug;5(8):597-609.

• 全文
• 摘要

82.  Janzen KM, Steuber TD, Nisly SA. GLP-1 agonists in type 1 diabetes mellitus. Ann Pharmacother. 2016 Aug;50(8):656-65.

• 摘要

83.  Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017 Dec 14;377(24):2337-48.

• 摘要

84.  Ahmed-Sarwar N, Nagel AK, Leistman S, et al. SGLT-2 inhibitors: is there a role in type 1 diabetes mellitus management? Ann Pharmacother. 2017 Sep;51(9):791-6.

• 摘要

85.  Henry RR, Thakkar P, Tong C, et al. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015 Dec;38(12):2258-65.

• 全文
• 摘要

86.  Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015 Oct;17(10):928-35.

• 全文
• 摘要

87.  Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015 Jul;38(7):1181-8.

• 全文
• 摘要

88.  White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010 May;59(5):1244-53.

• 摘要

89.  The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.

• 全文
• 摘要

90.  Pop-Busui RL, Low PA, Waberski BH, et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). Circulation. 2009 Jun 9;119(22):2886-93.

• 全文
• 摘要

91.  Nathan DM, Zinman B, Cleary PA, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983-2005). Arch Intern Med. 2009 Jul 27;169(14):1307-16.

• 全文
• 摘要

92.  Nathan DM, Cleary PA, Backlund JY, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 22;353(25):2643-53.

• 全文
• 摘要

93.  Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: The DCCT/EDIC Study 30-year follow-up. Diabetes Care. 2016 May;39(5):686-93.

• 全文
• 摘要

94.  Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010 May;33(5):1090-6.

• 全文
• 摘要

95.  Gagnum V, Stene LC, Jenssen TG, et al.Causes of death in childhood-onset type 1 diabetes: long-term follow-up. Diabet Med. 2017 Jan;34(1):56-63.

• 摘要

96.  American Diabetes Association. Hyperglycemic crises in diabetes. Diabetes Care. 2004 Jan;27(suppl 1):S94-102.

• 全文
• 摘要

97.  Finne P, Reunanen A, Steman S, et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA. 2005 Oct 12;294(14):1782-7.

• 全文
• 摘要

98.  Thomas MC, Atkins RC. Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs. 2006;66(17):2213-34.

• 摘要

99.  Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993 Apr;43(4):817-24.

• 摘要

100.  Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation. 2014 Jun 24;129(25 suppl 2):S49-73.

• 全文
• 摘要

101.  Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014 May;174(5):773-85.

• 全文
• 摘要

102.  National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. July 2016 [internet publication].

• 全文

103.  National Institute for Health and Care Excellence. Diabetes (type 1 and type 2) in children and young people: diagnosis and management. November 2016 [internet publication].

• 全文